Pedro Rosa Rosa-neto

Pedro Rosa Rosa-neto's AcademicInfluence.com Rankings

Engineering

#5980

World Rank

#7268

Historical Rank

Cybernetics

#108

World Rank

#114

Historical Rank

Biomedical Engineering

#490

World Rank

#500

Historical Rank

Electrical Engineering

#1721

World Rank

#1819

Historical Rank

engineering Degrees

Download Badge

Engineering

Pedro Rosa Rosa-neto's Degrees

PhD Neuroscience McGill University
Masters Biomedical Engineering McGill University
Bachelors Electrical Engineering University of Porto

Why Is Pedro Rosa Rosa-neto Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Pedro Rosa Rosa-neto's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template (2008) (1463)
Age- and Gender-Related Differences in the Cortical Anatomical Network (2009) (557)
Revealing modular architecture of human brain structural networks by using cortical thickness from MRI. (2008) (465)
Human brain white matter atlas: Identification and assignment of common anatomical structures in superficial white matter (2008) (461)
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts (2020) (452)
Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: Application to normal elderly and Alzheimer's disease participants (2009) (438)
Multi-level bootstrap analysis of stable clusters in resting-state fMRI (2009) (294)
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain (2017) (264)
Atlas-guided tract reconstruction for automated and comprehensive examination of the white matter anatomy (2010) (260)
Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist (2008) (259)
Consensus guidelines for lumbar puncture in patients with neurological diseases (2017) (197)
[18F]FDG PET signal is driven by astroglial glutamate transport (2017) (190)
Early-Onset Familial Alzheimer's Disease (EOFAD) (2012) (181)
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology (2021) (169)
Olfactory identification as a potential marker of presymptomatic Alzheimer's disease (2013) (166)
Astrocyte Biomarkers in Alzheimer's Disease. (2019) (147)
Age-related alterations in the modular organization of structural cortical network by using cortical thickness from MRI (2011) (147)
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative (2020) (133)
A multicentre validation study of the diagnostic value of plasma neurofilament light (2021) (130)
Microglial activation and tau propagate jointly across Braak stages (2021) (129)
Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder (2005) (128)
α-[11C]Methyl-l-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters (2006) (128)
Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) (2012) (128)
Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model (2014) (127)
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease (2019) (123)
Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. (2004) (117)
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. (2019) (108)
18F-MK-6240 PET for early and late detection of neurofibrillary tangles. (2020) (100)
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. (2021) (95)
In vivo quantification of neurofibrillary tangles with [18F]MK-6240 (2018) (95)
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease (2021) (94)
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease (2016) (92)
Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV (2017) (89)
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia (2020) (87)
Odor identification as a biomarker of preclinical AD in older adults at risk (2017) (84)
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging (2014) (84)
Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues (2013) (81)
Identifying incipient dementia individuals using machine learning and amyloid imaging (2017) (81)
Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer’s Disease (2017) (80)
Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer’s Disease with Combined Amyloid-β and Cerebrovascular Pathology (2013) (74)
Synergistic interaction between amyloid and tau predicts the progression to dementia (2017) (74)
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study (2019) (72)
Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals (2020) (71)
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease (2019) (67)
Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain (2003) (66)
Mapping neurotransmitter systems to the structural and functional organization of the human neocortex (2021) (63)
Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease (2017) (62)
VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis (2016) (62)
Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. (2005) (58)
Aβ-induced vulnerability propagates via the brain’s default mode network (2019) (55)
Limbic system mGluR5 availability in cocaine dependent subjects: A high-resolution PET [11C]ABP688 study (2014) (55)
4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (2012) (54)
Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar (2009) (52)
In vivo and in vitro Validation of Reference Tissue Models for the mGluR5 Ligand [11C]ABP688 (2010) (52)
Deletion of the mu opioid receptor gene in mice reshapes the reward–aversion connectome (2016) (51)
Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease (2021) (51)
Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment (2012) (50)
Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study (2006) (48)
Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. (2010) (48)
Anosognosia predicts default mode network hypometabolism and clinical progression to dementia (2018) (46)
Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease (2018) (46)
Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [11C]ABP688 PET (2015) (46)
Developments in Tau PET Imaging (2014) (45)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease (2017) (43)
Cholinergic Depletion in Alzheimer's Disease Shown by [18F]FEOBV Autoradiography (2013) (42)
Distinct Increased Metabotropic Glutamate Receptor Type 5 (mGluR5) in Temporal Lobe Epilepsy With and Without Hippocampal Sclerosis (2013) (41)
Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease (2018) (40)
MDMA‐evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain (2004) (39)
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility (2022) (39)
Consequences of Metabolic Disruption in Alzheimer’s Disease Pathology (2019) (38)
[18F]SiFA‐isothiocyanate: A New Highly Effective Radioactive Labeling Agent for Lysine‐Containing Proteins (2009) (37)
Guidelines for the content and format of PET brain data in publications and archives: A consensus paper (2020) (37)
Intact Memory in TGF-β1 Transgenic Mice Featuring Chronic Cerebrovascular Deficit: Recovery with Pioglitazone (2011) (37)
Superficially Located White Matter Structures Commonly Seen in the Human and the Macaque Brain with Diffusion Tensor Imaging (2011) (37)
MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research (2014) (37)
Surgical Resection for Intractable Epilepsy in “Double Cortex” Syndrome Yields Inadequate Results (2001) (37)
Imaging in vivo glutamate fluctuations with [11C]ABP688: a GLT-1 challenge with ceftriaxone (2015) (36)
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to (2018) (35)
Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [18F]fluoroethoxybenzovesamicol (2015) (35)
Determining Amyloid-β Positivity Using 18F-AZD4694 PET Imaging (2020) (34)
Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate results. (2001) (34)
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. (2020) (34)
Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: An autoradiographic study (2012) (34)
Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress (2018) (33)
Test‐retest stability of cerebral mGluR5 quantification using [11C]ABP688 and positron emission tomography in rats (2012) (33)
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression (2019) (33)
Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: Modulation by MAO-inhibition (2007) (33)
In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD (2016) (32)
Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET (2004) (32)
Machine Learning in Nuclear Medicine: Part 1—Introduction (2019) (32)
Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities (2017) (31)
APOEε4 potentiates the relationship between amyloid-β and tau pathologies (2020) (31)
PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV) (2012) (31)
Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia (2019) (31)
Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. (2018) (31)
Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease (2015) (30)
White Matter Abnormalities and Structural Hippocampal Disconnections in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease (2013) (30)
Imaging Alzheimer's disease pathophysiology with PET (2016) (30)
Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis (2018) (29)
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials (2020) (28)
Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease (2018) (28)
Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada (2016) (28)
Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. (2020) (28)
In vivo and in vitro validation of reference tissue models for the mGluR 5 ligand [ 11 C ] ABP 688 (2010) (27)
In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals (2014) (27)
Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues (2014) (27)
Differential early subcortical involvement in genetic FTD within the GENFI cohort (2021) (26)
Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies (2015) (26)
Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images (2019) (26)
Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes (2021) (26)
Resting state executive control network adaptations in amnestic mild cognitive impairment. (2014) (25)
Impact of scale space search on age‐ and gender‐related changes in MRI‐based cortical morphometry (2013) (25)
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease (2018) (25)
The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia (2018) (25)
Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease (2021) (25)
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) (25)
The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. (2020) (25)
Prevention strategies for Alzheimer’s disease (2012) (25)
Correlation between serotonin synthesis and 5-HT1A receptor binding in the living human brain: A combined α-[11C]MT and [18F]MPPF positron emission tomography study (2008) (25)
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians (2013) (24)
Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology? (2018) (24)
MDMA‐evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia (2004) (24)
Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 (2013) (24)
White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study (2019) (24)
Design, construction, and validation of an MRI-compatible vibrotactile stimulator intended for clinical use (2009) (23)
Morphometric network differences in ageing versus Alzheimer's disease dementia. (2020) (23)
Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation (2019) (23)
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis (2021) (23)
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease (2021) (23)
Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort (2020) (23)
Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents. (2015) (22)
Astrocyte Biomarkers in Alzheimer Disease (2021) (22)
Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 (2013) (22)
Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults (2020) (22)
Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: radiosynthesis and evaluation of 2-(4-[(18)F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl-(11)C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one. (2013) (21)
Inferior Longitudinal Fasciculus’ Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study (2019) (21)
Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging (2016) (20)
Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults (2019) (20)
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. (2021) (20)
Association of plasma P-tau181 with memory decline in non-demented adults (2021) (19)
Proximity to Parental Symptom Onset and Amyloid-&bgr; Burden in Sporadic Alzheimer Disease (2018) (19)
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid (2021) (19)
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease (2021) (18)
Test–retest variability of [11C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans (2018) (18)
MicroPET imaging of 5-HT1A receptors in rat brain: a test–retest [18F]MPPF study (2008) (18)
Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking (2017) (18)
A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia (2021) (17)
PET imaging with [¹⁸F]fluoroethoxybenzovesamicol ([¹⁸F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat. (2014) (17)
Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment (2020) (17)
Constrained instruments and their application to Mendelian randomization with pleiotropy (2017) (16)
A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. (2017) (16)
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease (2022) (16)
Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease (2022) (16)
Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV/AIDS and Breast Cancer. (2016) (16)
Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease. (2019) (16)
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy (2019) (15)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (15)
Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia (2019) (15)
First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. (2019) (15)
PET/CT of Dementia. (2018) (14)
Brain regional α-[11C]methyl-L-tryptophan trapping, used as an index of 5-HT synthesis, in healthy adults: absence of an age effect (2007) (14)
The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database (2017) (14)
Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes (2015) (14)
Prevalence and family-related factors associated with suicidal ideation, suicide attempts, and self-injury in children aged 9 to 10 years (2020) (14)
Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease (2020) (14)
Stability of α-[11C]methyl-l-tryptophan brain trapping in healthy male volunteers (2005) (14)
Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T (2009) (14)
Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET (2022) (13)
Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease (2020) (13)
In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy (2019) (13)
Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry (2013) (13)
PET imaging of freely moving interacting rats (2019) (13)
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease? (2016) (13)
A-( 11 C)Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide (2006) (13)
Remodeling of Neuronal Circuits After Reach Training in Chronic Capsular Stroke (2016) (12)
Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals (2021) (12)
Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain (2017) (12)
Motion compensation for fully 4D PET reconstruction using PET superset data (2010) (12)
Amyloid processing in COVID‐19‐associated neurological syndromes (2022) (12)
Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation. (2019) (12)
TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation. (2010) (11)
Diagnostic value of plasma neurofilament light: A multicentre validation study (2020) (11)
Use of Biomarkers in Clinical Trials of Alzheimer Disease (2011) (11)
Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. (2011) (11)
Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV. (2021) (10)
Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies (2016) (10)
Staging of Alzheimer's disease: past, present, and future perspectives. (2022) (10)
Interactive rather than independent effect of APOE and sex potentiates tau deposition in women (2021) (10)
Epistasis analysis links immune cascades and cerebral amyloidosis (2015) (10)
Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography (2022) (10)
The calcium sensor synaptotagmin-1 is critical for phasic axonal dopamine release in the striatum and mesencephalon, but is dispensable for basic motor behaviors in mice (2021) (9)
Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease (2021) (9)
18F-MK-6240 tau-PET in genetic frontotemporal dementia (2021) (9)
Time-efficient and convenient synthesis of [(18)F]altanserin for human PET imaging by a new work-up procedure. (2009) (9)
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease (2021) (9)
Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study (2021) (8)
Machine Learning in Nuclear Medicine: Part 2—Neural Networks and Clinical Aspects (2020) (8)
Creation of an Open Science Dataset from PREVENT-AD, a Longitudinal Cohort Study of Pre-symptomatic Alzheimer’s Disease (2020) (8)
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease (2020) (8)
Publisher Correction: Microglial activation and tau propagate jointly across Braak stages (2021) (8)
Sensory-parietal cortical stimulation improves motor recovery in severe capsular infarct (2016) (7)
Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer’s disease (2017) (7)
Case studies in dementia : common and uncommon presentations (2011) (7)
Disease-related cortical thinning in presymptomatic granulin mutation carriers (2020) (7)
Cholinergic Modulation of Binocular Vision (2020) (7)
CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem (2018) (7)
Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views (2021) (7)
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals (2021) (7)
Characterizing biomarker features of cognitively normal individuals with ventriculomegaly (2017) (7)
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging (2022) (7)
A simplified radiosynthesis of [18 F]MK-6240 for tau PET imaging. (2019) (7)
Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment (2018) (6)
Dynamic 1H‐MRS for detection of 13C‐labeled glucose metabolism in the human brain at 3T (2020) (6)
Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer’s Disease Spectrum (2019) (6)
INTREPAD (2019) (6)
Wrappers Feature Selection in Alzheimer's Biomarkers Using kNN and SMOTE Oversampling (2017) (6)
Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging (2019) (6)
Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer’s disease (2022) (6)
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment (2020) (6)
Clozapine induces astrocyte-dependent FDG-PET hypometabolism (2021) (6)
Stability of alpha-[11C]methyl-L-tryptophan brain trapping in healthy male volunteers. (2005) (5)
Towards the PET radiotracer for p75 neurotrophin receptor: [(11)C]LM11A-24 shows biological activity in vitro, but unfavorable ex vivo and in vivo profile. (2016) (5)
Investigating the Roles of Anterior Cingulate in Behavioral Variant Frontotemporal Dementia: A PET/MRI Study (2021) (5)
CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment (2021) (5)
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease (2021) (5)
Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease (2020) (5)
Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging (2020) (5)
[11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease (2022) (5)
Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs (2020) (5)
A brain signature highly predictive of future progression to Alzheimer's dementia (2017) (4)
Efficient radiosynthesis and preclinical evaluation of [18 F]FOMPyD as a PET tracer candidate for TrkB/C receptor imaging. (2020) (4)
IMAGING EPIGENETICS IN THE HUMAN BRAIN WITH THE NOVEL [11C]MARTINOSTAT PET IN PRECLINICAL AD, MCI, AD, AND FRONTOTEMPORAL DEMENTIA INDIVIDUALS (2018) (4)
AN AMYLOID LIGAND-FREE OPTICAL RETINAL IMAGING METHOD TO PREDICT CEREBRAL AMYLOID PET STATUS (2018) (4)
Molecular Imaging of Alzheimer ’ s Disease Using PET (2008) (4)
Reconfigured metabolism brain network in asymptomatic microtubule-associated protein tau mutation carriers: a graph theoretical analysis (2022) (4)
Temporal order of clinical and biomarker changes in familial frontotemporal dementia (2022) (4)
Motion-compensated fully 4D PET reconstruction using PET data supersets (2009) (4)
Optimal use of cholinergic drugs in Alzheimer's disease. (2018) (4)
How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer's Disease? (2013) (4)
FEOBV‐PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry (2021) (4)
Frontotemporal dementia and COVID‐19: Hypothesis generation and roadmap for future research (2020) (4)
Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients (2016) (4)
Development of FMRI techniques for planning in functional neurosurgery for Parkinson’s disease (2008) (4)
Imaging biomarkers for amyloid: a new generation of probes and what lies ahead (2014) (4)
Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans (2020) (4)
No apparent effect of naproxen on CSF markers of innate immune activation (2019) (4)
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease (2022) (4)
Multi-level bootstrap analysis of stable clusters (BASC) in resting-state fMRI (2009) (3)
Resting state executive control network adaptations in amnestic mild cognitive impairment (2013) (3)
[18F]NAV4694 shows higher binding and wider dynamic range compared with [11C]PiB in Alzheimer's disease postmortem tissue (2013) (3)
Dosimetry of PET tracers in mice using microPET scans as an input function (2005) (3)
Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study (2022) (3)
Unified epigenomic, transcriptomic, proteomic, and metabolomic taxonomy of Alzheimer’s disease progression and heterogeneity (2022) (3)
Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults (2022) (3)
Preliminary Evaluations of [11C]Verubulin: Implications for Microtubule Imaging With PET (2021) (3)
CCCDTD5: research diagnostic criteria for Alzheimer's Disease (2020) (3)
PET Imaging of Perceptual Learning-Induced Changes in the Aged Rodent Cholinergic System (2020) (3)
Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum (2022) (3)
Artificial intelligence for molecular neuroimaging (2021) (3)
Proposal of new diagnostic criteria for fatal familial insomnia (2022) (3)
Declines of hippocampal metabotropic glutamate receptor in Alzheimer's disease (2009) (3)
[18F]NAV4694 shows higher binding and wider dynamic range compared with [11C]PiB in Alzheimer's disease postmortem tissue (2013) (3)
Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies (2023) (3)
LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY (2017) (3)
Dementia: Disclosure of results to participants in dementia research (2013) (3)
Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic (2021) (3)
APOE4 packs a punch in women: Sex‐specific vulnerability for tau and neuroinflammation (2020) (2)
Vascular risk burden is a key player in the early progression of Alzheimer's disease (2021) (2)
Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study (2015) (2)
Comment on “Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases” (2022) (2)
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition. (2022) (2)
LONGITUDINAL FOLLOW-UP OF AMYLOIDOSIS AND GLUCOSE HYPOMETABOLISM IN A TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE (2014) (2)
AN AMYLOID LIGAND-FREE OPTICAL RETINAL IMAGING METHOD TO PREDICT CEREBRAL AMYLOID PET STATUS (2018) (2)
Resting-state connectivity impairment in a rat model of Alzheimer's disease (2013) (2)
FUNCTIONAL REGRESSION MODEL UNVEILS THAT GENE INTERACTION BETWEEN NCSTN (AMYLOID METABOLISM) AND MS4A4E (NEUROINFLAMMATION) DETERMINES AMYLOID LOAD SPECIFICALLY ON THE DMN (2017) (2)
Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia (2022) (2)
Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset (2021) (2)
Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine? (2014) (2)
Social isolation is linked to classical risk factors of Alzheimer’s disease-related dementias (2021) (2)
In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD (2015) (2)
Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives (2014) (2)
Neuromelanin-Sensitive MRI as an Index of Norepinephrine System Integrity in Healthy Aging, Mild Cognitive Impairment, and Alzheimer’s Disease (2020) (2)
Aβ 34 is a BACE 1-derived degradation intermediate associated with amyloid clearance and Alzheimer ’ s disease progression (2019) (2)
CNTN5 is associated with disease risk and pathology throughout the Alzheimer’s disease continuum (2021) (2)
CLINICAL IMPACT OF CSF ASSESSMENT ON DIAGNOSTIC ACCURACY IN ATYPICAL DEMENTIAS IN QUEBEC, CANADA: PRELIMINARY RESULTS FROM A SPECIALIZED DEMENTIA CLINIC (2019) (2)
Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia (2021) (2)
Tau‐PET is associated with knowledge of COVID‐19, COVID‐19‐related distress, and change in sleep quality during the pandemic (2021) (1)
Declines of hippocampal metabotropic glutamate receptor in Alzheimer's disease (2009) (1)
Prevention strategies for Alzheimer’s disease (2012) (1)
Test–retest stability of cerebral mGluR5 quantification using [11C]ABP688 and PET in rats (2010) (1)
IN VIVO AND IN VITRO DEMONSTRATION OF [18F]THK5351 BINDING TO MONOAMINE OXIDASE–B IN THE HUMAN BRAIN (2017) (1)
Baseline Neurodegeneration Influences the Longitudinal Effects of Tau on Cognition. (2021) (1)
CSF MARKERS OF INFLAMMATION AND ALZHEIMER'S DISEASE PATHOGENESIS IN THE COGNITIVELY INTACT PREVENT-AD COHORT (2016) (1)
Plasma Levels of Phosphorylated Tau 181 Are Associated With Cerebral Metabolic Dysfunction in Cognitively Impaired Individuals (2020) (1)
Bilingualism is associated with lower cognitive decline and with lower levels of AD biomarkers in a cognitively unaffected cohort (2021) (1)
Resting-state connectivity impairment in a rat model of Alzheimer's disease (2013) (1)
Phantom bedside intruder in Parkinson's disease (2018) (1)
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging (2014) (1)
Hypercholesterolemia accelerates Aβ deposition in regions associated with early amyloidosis (2020) (1)
Generation of Functional Images of The Brain Trapping Constant for α-[11C]Methyl-L-Tryptophan Using Constrained Linear Regression (2011) (1)
NEURODEGENERATION AND CORTICAL ATROPHY IN [18F]FLORBETAPIR ACCUMULATORS AND NON-ACCUMULATORS (2014) (1)
Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology (2020) (1)
A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment (2016) (1)
The neuroinflammation signatures in different stages of the Alzheimer’s disease continuum (2021) (1)
Stable brain PET metabolic networks using a multiple sampling scheme (2021) (1)
Microglia activation predicts tau positivity beyond Aβ in Alzheimer’s disease (2021) (1)
Serum cholesterol levels and APOEε4 status potentiate metabolic decline in non‐demented individuals (2020) (1)
Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease (2017) (1)
Clinical Meaningfulness of Biomarker Endpoints in Alzheimer’s Disease Research (2018) (1)
Specific structuro-metabolic pattern of thalamic subnuclei in fatal familial insomnia: A PET/MRI imaging study (2022) (1)
Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors. (2022) (1)
Correction: White Matter Abnormalities and Structural Hippocampal Disconnections in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease (2013) (1)
EARLY INCREASE IN TAU-PET SIGNAL IS ASSOCIATED WITH Aβ BURDEN, CSF P-TAU LEVELS AND COGNITION IN COGNITIVELY NORMAL LATE-MIDDLE-AGED ADULTS (2018) (1)
Reduced [ 18 F]flortaucipir retention in white matter hyperintensities compared to normal‐appearing white matter: Neuroimaging / Optimal neuroimaging measures for tracking disease progression (2020) (1)
Potential utility of plasma p-tau and NfL as surrogate biomarkers for preventive clinical trials (2022) (1)
Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia (2020) (1)
In vivo hippocampal cornu ammonis 1–3 glutamatergic abnormalities are associated with temporal lobe epilepsy surgery outcomes (2021) (1)
Mapping the progression of CSF and imaging biomarkers in “at-risk” healthy subjects: The prevent-ad program (2015) (1)
Medial temporal neuroinflammation unleashes tau spreading over the neocortex (2020) (1)
Regional distribution of fibrillar amyloid deposition in the brain as a function of CSF beta-amyloid 1-42 and biomarkers of neurodegeneration (2013) (1)
Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls (2020) (1)
Brain amyloid deposition and metabolism in early and late mild cognitive impairment (2012) (1)
Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24 months' follow-up in cognitively normal subjects (2015) (1)
How to follow up and cluster subjects by longitudinal changes of fibrillary amyloid imaging and CSF biomarkers? a 24-month follow up (2015) (1)
Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment (2021) (1)
Impact of long- and short-range fiber depletion on the cognitive deficits of fronto-temporal dementia (2020) (1)
Hippocampal resting-state connectivity lateralize memory function in aMCI brain networks (2011) (1)
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology (2021) (1)
Involvement of striatal motoric subregions in familial frontotemporal dementia with parkinsonism harboring the C9orf72 repeat expansions (2022) (1)
Confrontation naming deficits are associated with amyloidosis in early MCI and with synaptic dysfunction in late MCI and Alzheimer's disease: An [18F]AV45/[18F]FDG-PET study (2012) (1)
CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer’s disease (2021) (1)
CSF apolipoprotein B is associated with early tau pathology and selective activation of a cytokine cascade in cognitively unaffected subjects with a parental history of Alzheimer’s disease (2021) (1)
Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease (2018) (1)
Fluid biomarkers for diagnosing dementia : rationale and recommendations for Canadian Physicians (2012) (1)
pTau heterogeneity as a measure for disease severity in incipient Alzheimer's disease (2022) (1)
Diagnosis of Alzheimer’s disease (2012) (1)
Plasma phospho-tau181 as a biomarker for Alzheimer’s disease: development and validation of a prediction model using data from four prospective cohorts (2020) (1)
In vivo tau staging in Alzheimer’s disease (2022) (1)
CORRELATIONS BETWEEN VARIOUS MOCA COGNITIVE DOMAIN ASSESSMENTS AND REGIONAL BRAIN FDG-PET HYPOMETABOLISM (2014) (1)
Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases (2022) (1)
Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 (2013) (1)
Advances in Alzheimer’s Disease Management (2012) (1)
Brain beta-amyloid deposition and metabolism in early and late mild cognitive impairment (2012) (1)
CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals (2022) (1)
GLUCOSE METABOLISM IMPACT ON FUNCTIONAL CONNECTIVITY IN ALZHEIMER'S DISEASE (2014) (1)
Medial temporal tau predicts memory decline in cognitively unimpaired elderly (2022) (1)
Neuroinflammation is associated with non‐REM sleep reduction in individuals without dementia (2020) (1)
Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET (2023) (1)
COMPETITIVE BINDING OF [11C]PIB AND [18F]NAV4694 IN A TRANSGENIC RAT MODEL OF AMYLOIDOSIS (2014) (1)
In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals (2014) (1)
Differential impact of amyloidosis and tau pathology on brain metabolism (2013) (1)
IN VITRO PROPERTIES OF [18F]NAV4694: DYNAMIC RANGE, DISPLACEMENT, AND WHITE-MATTER BINDING (2014) (1)
Development of a new fMRI compatible pneumatic vibrotactile stimulator (2007) (1)
Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations (2022) (1)
BRAIN EPIGENETIC CHANGES MEASURED WITH THE NOVEL [11C]MARTINOSTAT PET MEDIATE THE EFFECTS OF AMYLOID AND TAU PET DEPOSITION ON COGNITION (2018) (1)
The CBI‐R detects early behavioural impairment in genetic frontotemporal dementia (2022) (1)
EARLY INCREASE IN TAU-PET SIGNAL IS ASSOCIATED WITH Aβ BURDEN, CSF P-TAU LEVELS AND COGNITION IN COGNITIVELY NORMAL LATE-MIDDLE-AGED ADULTS (2018) (1)
GRAPH-THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION (2017) (1)
ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER’S DISEASE (2019) (1)
3D MRI Brain Tumour Segmentation with Autoencoder Regularization and Hausdorff Distance Loss Function (2021) (1)
Should a global or a regional measure of amyloidosis be used in a longitudinal study? (2015) (1)
APOEε4 POTENTIATES THE RELATIONSHIP BETWEEN AMYLOID-β AND TAU PATHOLOGIES IN A DOSE-DEPENDENT MANNER (2018) (1)
Consistent inter-protocol differences in resting-state functional connectomes between normal aging and mild cognitive impairment (2015) (1)
Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians (2013) (1)
Kundalini Yoga Intervention Increases Hippocampal Volume in Older Adults: A Pilot Randomized Controlled Trial (2022) (0)
VOXEL-WISE LOGISTIC REGRESSION IMPROVES PREDICTION ACCURACY FOR DEVELOPING AD (2016) (0)
APOEÏµ4 carriership associates with microglial activation independently of AÎ² plaques and tau tangles (2022) (0)
COMBINED GLOBAL AND REGIONAL AMYLOID EFFECT ON THE DEFAULT MODE NETWORK LEADS TO COGNITIVE DECLINE (2017) (0)
Multiresolution functional brain parcellation in an elderly population with no or mild cognitive impairment (2016) (0)
TRIAD multi‐dimensional biobank for biomarker discovery (2022) (0)
Editorial: Expanding the atn Framework to Further Personalize Therapies (2023) (0)
Longitudinal changes in plasma p‐tau181 as a surrogate variable to populational interventions (2022) (0)
DIFFERENT DIAGNOSIS GUIDELINES ON THE ALZHEIMER’S DISEASE CONTINUUM (2019) (0)
AMYLOIDOSIS CHANGES ASSOCIATIONS BETWEEN HIPPOCAMPUS VOLUME AND BRAIN METABOLIC DECLINES (2014) (0)
MOVING AWAY FROM SINGLE AD-SIGNATURE ROI: ASSESSING THE RELATIONSHIP BETWEEN WHOLE-BRAIN GRAY MATTER PATTERN, AD PATHOLOGY, AND COGNITION IN HEALTHY ELDERLY AT RISK OF AD (2017) (0)
Mild behavioral impairment symptom severity predicts tau hyperphosphorylation assessed by plasma p‐tau181 across the Alzheimer’s disease spectrum (2022) (0)
PET NEUROIMAGING OF CHOLINERGIC DEPLETION IN ALZHEIMER DISEASE (AD) USING [18F]-FLUOROETHOXYBENZOVESAMICOL: A POTENTIAL BIOMARKER. (2016) (0)
White Matter Hyperintensity as a Vascular Contribution to the AT(N) Framework (2023) (0)
Reliability and sensitivity to detect cortical cholinergic denervation in rats using PET imaging with [18F]Fluoroethoxybenzovesamicol (2011) (0)
REGIONAL ASSOCIATION MAPS DESCRIBE DYNAMIC ARCHITECTURE OF AMYLOIDOSIS AND HYPOMETABOLISM IN ALZHEIMER'S DISEASE (2014) (0)
Verbal recognition declines in later Braak Stages compared to verbal delayed recall (2022) (0)
Visual memory scores are associated with lateralization of tau in the medial temporal lobe (2021) (0)
MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas (2023) (0)
Cognitive reserve: Evaluating the relationship between WASI‐II Matrix Reasoning and tau accumulation using [18F]MK6240 in monolingual and bilingual individuals (2021) (0)
MILD BEHAVIORAL IMPAIRMENT IS ASSOCIATED WITH β-AMYLOID BUT NOT WITH TAU IN COGNITIVELY INTACT ELDERLY INDIVIDUALS (2019) (0)
THE ASSOCIATION BETWEEN WHITE MATTER HYPERINTENSITIES AND MEMORY IMPAIRMENT DEPENDS ON P-TAU LEVELS IN A HIGH-RISK COHORT OF AGING COGNITIVELY NORMAL PERSONS (2016) (0)
Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease (2023) (0)
Association between cortical thickness and CSF biomarkers in mild cognitive impairment and Alzheimer’s disease (2013) (0)
COGNITIVE DECLINE IS DRIVEN BY THE REGIONAL SYNERGISM BETWEEN AMYLOID LOAD AND HYPOMETABOLISM IN MILD COGNITIVE IMPAIRMENT (2016) (0)
Discrepancy between plasma pTau181 and tau‐PET statuses (2021) (0)
BRAIN DELIVERY OF AN AMYLOID-β OLIGOMER (AβO)-TARGETING PEPTIDE-THERAPEUTIC BY A NOVEL BLOOD-BRAIN BARRIER (BBB)-CROSSING DOMAIN ANTIBODY (2017) (0)
UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXEL-WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS (2018) (0)
EARLY REMODELING OF BRAIN METABOLIC ARCHITECTURE IN A TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE (2014) (0)
Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiology (2022) (0)
SUBTHRESHOLD LEVEL TAU DEPOSITION OCCURS PRIOR TO SUBTHRESHOLD AMYLOID DEPOSITION IN COGNITIVELY NORMAL ELDERLY INDIVIDUALS (2019) (0)
ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER’S DISEASE (2019) (0)
Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light (2021) (0)
[18F]FLORBETAPIR ROC CURVE AT EVERY VOXEL REVELS A WIDE RANGE OF CORTICAL SUVR CUT-OFFS (2016) (0)
Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada (2020) (0)
AMYLOIDOSIS INDUCES EARLY METABOLIC REORGANIZATION (2019) (0)
Clinical utility of amyloid PET in the differential diagnosis of atypical dementias and its impact on caregivers (2015) (0)
FDG-PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER’S DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS (2017) (0)
Effect of temporal meta‐ROI and Braak1&2 ROI on the dissociation between plasma pTau181 and PET statuses (2021) (0)
Blood protein kinase activity regulating genes are associated with brain glucose metabolism (2022) (0)
HIPPOCAMPAL ATROPHY IN THE MCGILL-R-THY1-APP RAT MODEL OF ALZHEIMER'S DISEASE: A FOLLOW UP STUDY (2014) (0)
TBD (2011) (0)
Aging and sex effects on the cortical anatomical network efficiency (2009) (0)
EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNORESPONSE (2014) (0)
THE SYNERGISTIC INTERACTION BETWEEN AMYLOID AND TAU DISRUPTS LOCAL AND GLOBAL RESTING STATE FMRI CONNECTIVITY (2018) (0)
How to follow up and cluster subjects by longitudinal changes of fibrillary amyloid imaging and CSF biomarkers? 24-month follow up (2015) (0)
Genome-wide association study in PET imaging longitudinal data (2015) (0)
AMYLOID-BETA 1-42 (Aβ1-42) LEVELS IN THE CEREBROSPINAL FLUID ASSOCIATE WITH SPATIAL MEMORY PERFORMANCE IN AGED BUT NOT IN ADULT MCGILL-R-THY1-APP RATS (2016) (0)
Association between memory and amyloid deposition and synaptic dysfunction in EMCI, LMCI and Alzheimer’s disease patients (2013) (0)
POLYMORPHISM IN CYTOCHROME P450 GENE IS ASSOCIATED WITH ALZHEIMER’S PATHOLOGY (2016) (0)
LONGITUDINAL FOLLOW-UP OF AMYLOIDOSIS AND GLUCOSE HYPOMETABOLISM IN A TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE (2014) (0)
THE EFFECT OF PROTON PUMP INHIBITORS AND CYP2C19 ON AMYLOID PATHOLOGY (2018) (0)
In vivo characterization of metabotropic glutamate receptor type five vulnerability in behavioral variant FTD and Alzheimer's disease: An [11C]ABP688 PET/ VBM /DBM study (2013) (0)
Regional distribution of brain fibrillar amyloid deposition as a function of CSF beta-amyloid 1-42 and biomarkers of neurodegeneration (2013) (0)
Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP rat (2015) (0)
Should a global or a regional measure of amyloidosis be used in a longitudinal study? (2015) (0)
ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER’S DISEASE (2019) (0)
Case Studies in Dementia: Introduction to the diagnosis of dementia (2011) (0)
IN VITRO QUANTIFICATION OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE: AN [18F]T807 AUTORADIOGRAPHIC STUDY (2014) (0)
IC‐P‐025: Withdrawn (2015) (0)
Cover Image (2018) (0)
Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease (2021) (0)
Different relationship of cross‐regional correlations of progression of local cortical thickness and local SUVR 18F‐flortaucipir PET values to strength of connectivity (2020) (0)
VOXEL-WISE DETERMINATION OF SENSITIVITY, SPECIFICITY, AND THRESHOLDS FOR AMYLOID POSITIVITY USING [18F]FLORBETAPIR PET (2017) (0)
Altered metabolic connectivity within the limbic cortico-striato-thalamo-cortical circuit in presymptomatic and symptomatic behavioral variant frontotemporal dementia (2023) (0)
THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION (2018) (0)
Cerebral amyloid deposition correlates with objectively measured sleep dysfunction (2020) (0)
Serine/threonine kinase activity associates with brain glucose metabolism changes in Alzheimer's Disease (2022) (0)
[ 18 F]MK‐6240 depicts early and late Braak stages of neurofibrillary tangles in preclinical and symptomatic subjects: Neuroimaging / Optimal neuroimaging measures for early detection (2020) (0)
Microglial sex dimorphism poses greater vulnerability to Alzheimer’s disease in females: A cross‐species study (2020) (0)
Different relationship of cross‐regional correlations of progression of local cortical thickness and local SUVR 18F‐Flortaucipir PET values to strength of connectivity (2020) (0)
YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER DISEASE (2017) (0)
Association between brain amyloidosis, synaptic dysfunction and cognitive performance measured with ADAS-cog and MMSE scores in EMCI, LMCI and Alzheimer's disease (2012) (0)
Association between brain amyloidosis, synaptic dysfunction and cognitive performance measured with ADAS-cog and MMSE scores in early MCI, late MCI and Alzheimer's disease (2012) (0)
[18F]MK‐6240 depicts early and late Braak stages of neurofibrillary tangles in preclinical and symptomatic subjects (2020) (0)
COVID‐19 pandemic: Quantifying the effects of the first lockdown on behavioral and cognitive measures using TASIC (2021) (0)
Association between cortical thickness and CSF biomarkers in mild cognitive impairment and Alzheimer's disease (2013) (0)
Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease (2023) (0)
Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies (2023) (0)
Clinical relevance of disrupted topological organization of anatomical connectivity in behavioral variant frontotemporal dementia (2023) (0)
Applications of Alzheimer’s disease staging to clinical trials (2023) (0)
DECREASED WHITE MATTER FIBER CROSS-SECTION IS ASSOCIATED TO NORMAL AGING AND HIGHER TAU DEPOSITION INDEPENDENTLY OF AMYLOID (2019) (0)
Distribution of [11C]-JNJ-42491293 in the marmoset brain: a positron emission tomography study. (2023) (0)
Distinct changes in morphometric networks in aging versus Alzheimer’s disease dementia (2019) (0)
Mass spectrometric measurement of six site‐specific tau phosphorylations in CSF and blood of Alzheimer's disease patients (2021) (0)
LACK OF SELF-AWARENESS OF COGNITIVE DEFICITS IN ALZHEIMER’S DISEASE IS RELATED TO DECREASED METABOLISM IN THE POSTERIOR CINGULATE CORTEX (2017) (0)
GLUCOSE METABOLISM IMPACT ON FUNCTIONAL CONNECTIVITY IN ALZHEIMER'S DISEASE (2014) (0)
Cross-species comparative hippocampal transcriptomics in Alzheimer’s disease (2023) (0)
P.111 In vivo hippocampal mGluR5 abnormalities predict MTLE post-surgical outcome (2022) (0)
PARIETAL WHITE MATTER TRACT ALTERATIONS IN MCI AND ALZHEIMER'S DISEASE PATIENTS FROM THE ADNI DATASET (2014) (0)
Management of agitation and aggression: controversies and possible solutions (2012) (0)
THE “A/T/N” SYSTEM: ADDED PREDICTIVE VALUE OF N BIOMARKERS OF PROGRESSION FROM MCI TO DEMENTIA OVER 2 AND 4 YEARS (2017) (0)
Genetic risk for attention‐deficit/hyperactivity disorder is associated with amyloid‐dependent cognitive decline in older adults (2022) (0)
Mapping the progression of vascular CSF biomarkers in pre-symptomatic “at-risk” healthy subjects in the PREVENT-AD program (2017) (0)
CORRELATION BETWEEN CSF T-TAU AND P-TAU WITH [18F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2018) (0)
Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study (2022) (0)
A novel P75‐neurotrophin receptor antagonist, EVT901, reduces neuroinflammation in the TGFAD344 rat model of Alzheimer’s disease (2020) (0)
LOGICAL MEMORY DEFICITS ACROSS ALZHEIMER’S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF A TAU PROPAGATION PREDICTED BY BRAAK STAGING (2018) (0)
Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification. (2022) (0)
Revealing the combined roles of Aβ and tau in Alzheimer’s disease via a pathophysiological activity decoder (2023) (0)
Defining an optimal approach for evaluating regional metabolism with 18F-FDG-PET imaging: Anatomical versus probabilistic volumes of interest (2012) (0)
Cognitive composites for genetic frontotemporal dementia: GENFI-Cog (2022) (0)
Plasma p‐tau231 in the Alzheimer’s disease continuum: A multi‐cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application (2021) (0)
Profiling tau accumulation with SPReAD: Sub‐stages for propagation regions in Alzheimer's disease (2021) (0)
P1–148: Withdrawn (2013) (0)
Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease (2018) (0)
[18F]MK6240 PET TAU BINDING IN ATYPICAL AD AND NON-AD TAUOPATHIES (2018) (0)
Evaluation of a retinal deep phenotyping platform to detect the likely cerebral amyloid PET status in humans (2020) (0)
LONGITUDINAL COLLECTION OF CEREBROSPINAL FLUID IN RATS: A MINIMALLY INVASIVE METHOD (2014) (0)
THE TRANSLATIONAL BIOMARKERS IN AGING AND DEMENTIA: TRIAD, A BIOMARKER ORIENTED COHORT (2019) (0)
LATERAL TEMPORAL AMYLOID LOAD PREDICTS PROGRESSION TO ALZHEIMER’S DEMENTIA (2018) (0)
CORTICAL IRON DEPOSITION IN ALZHEIMER’S DISEASE CONTRASTS WITH AGE-RELATED SUBCORTICAL DEPOSITION (2019) (0)
Amyloid and tau‐driven signatures in hippocampal GFAP‐positive astrocytes (2022) (0)
PREDICTING TAU PATHOLOGY PROGRESSION IN ALZHEIMER’S DISEASE BY MATHEMATICAL SIMULATION: FURTHER RESULTS AND PRIORITIZATION OF MODIFICATIONS FOR FURTHER IMPROVEMENTS (2019) (0)
Association between tau uptake and verbal fluency converge in language centers (2022) (0)
AMYLOID-BETA MODULATES CEREBRAL METABOLIC NETWORK IN RATS AND HUMANS (2017) (0)
Amyloid and tau pathologies associate with distinct aspects of the inflammatory cascade (2022) (0)
Extensive white matter burden represents a new radiological phenotype in a distinct population of ad patients (2015) (0)
A Challenging Thesis (2021) (0)
CORRELATION BETWEEN CSF T-TAU AND P-TAU WITH [18F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2018) (0)
Reconfigured metabolism brain network in asymptomatic microtubule-associated protein tau mutation carriers: a graph theoretical analysis (2022) (0)
ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT AND WHITE MATTER DENSITY IN ALZHEIMER’S DISEASE (2019) (0)
Cerebrospinal fluid ad biomarkers predict poorer cognitive performance in a cognitively intact cohort at risk of Alzheimer’s dementia: The prevent-ad program (2015) (0)
Normative Values of Neuromelanin-Sensitive MRI Signal in Older Adults Obtained Using a Turbo Spin Echo Sequence. (2022) (0)
High-yielding, automated radiosynthesis of [11 C]martinostat using [11 C]methyl triflate. (2022) (0)
Longitudinal changes in brain glucose metabolism, astrocyte biomarkers and behavior in an APP/PS1 rat model (2022) (0)
ASSOCIATION BETWEEN NEUROINFLAMMATION (LEVEL) AND VERBAL AND VISUAL MEMORY PERFORMANCE IN HIGH AFFINITY BINDERS (2019) (0)
A longitudinal 18F-FDG PET/MRI study in asymptomatic stage of genetic Creutzfeldt–Jakob disease linked to G114V mutation (2022) (0)
Tau phosphorylation is more closely associated with amyloid‐β plaques than with tau neurofibrillary tangles (2022) (0)
IN VITRO PROPERTIES OF [18F]NAV4694: DYNAMIC RANGE, DISPLACEMENT, AND WHITE-MATTER BINDING (2014) (0)
Suicidal ideation is common in autosomal dominant Alzheimer's disease at‐risk persons (2020) (0)
ISSUES REGARDING [18F]MK6240 REFERENCE REGION SELECTION BASED ON THE FULL KINETIC MODELING (2019) (0)
Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study (2022) (0)
Man with problems with reading and calculating (2011) (0)
Association between memory and amyloid deposition–synaptic dysfunction in people with EMCI, LMCI and Alzheimer’s disease (2013) (0)
ISSUES REGARDING [18F]MK6240 REFERENCE REGION SELECTION BASED ON THE FULL KINETIC MODELING (2019) (0)
LACK OF SELF-AWARENESS OF COGNITIVE DEFICITS PREDICTS DEFAULT MODE NETWORK METABOLIC DECLINE IN MILD COGNITIVE IMPAIRMENT (2017) (0)
Dizziness in someone with HIV (2011) (0)
Brain morphometric and metabolic changes in Subjective Cognitive Decline individuals (2022) (0)
Plasma levels of an N‐terminal tau fragment predict core AD and neurodegenerative biomarkers in autosomal dominant Alzheimer’s disease: Findings from DIAN (2022) (0)
REGIONAL ASSOCIATION MAPS DESCRIBE DYNAMIC ARCHITECTURE OF AMYLOIDOSIS AND HYPOMETABOLISM IN ALZHEIMER'S DISEASE (2014) (0)
YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER’S DISEASE (2017) (0)
TAU AND AMYLOID PATHOLOGY SUPPRESS GLOBAL BRAIN FUNCTIONAL CONNECTIVITY (2019) (0)
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. (2022) (0)
P3-427 MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIAWITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AV-1451 UPTAKE (2019) (0)
LACK OF SELF-AWARENESS OF COGNITIVE DEFICITS IN ALZHEIMER’S DISEASE IS RELATED TO DECREASED METABOLISM IN THE POSTERIOR CINGULATE CORTEX (2017) (0)
The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort (2021) (0)
Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification (2022) (0)
Amyloidosis induces reorganization of the hippocampal metabolic network (2015) (0)
Posterior cingulate network adaptation in Alzheimer's disease (2013) (0)
LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER’S DISEASE (2019) (0)
The interplay between functional MRI measures of episodic memory and CSF measures of tau in healthy adults at risk of Alzheimer’s Disease (2022) (0)
Reduced Metabotropic Glutamate Receptor Type 5 Availability in the Epileptogenic Hippocampus: An in vitro Study (2022) (0)
Amyloidosis induces reorganization of the hippocampal metabolic network (2015) (0)
GRAPH-THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION (2017) (0)
Modeling the trajectory of tau deposition in autosomal‐dominant Alzheimer’s disease using the high‐affinity tau tracer [18F]MK6240 (2020) (0)
AMYLOID-DEPENDENT AND AMYLOID-INDEPENDENT EFFECTS OF TAU ON CLINICAL STATUS (2019) (0)
Synergistic underpinning of global amyloid and cingulate neuroinflammation underlies tau propagation in Alzheimer’s disease (2020) (0)
SYNERGISM BETWEEN BRAIN AMYLOID ACCUMULATION AND NEURONAL INJURY IN CORTICAL-SUBCORTICAL CIRCUITS CAUSES MEMORY DECLINES IN ANIMAL MODELS (2016) (0)
SYNERGISM BETWEEN BASELINE AMYLOIDOSIS AND NEURONAL INJURY AS DETERMINANTS OF LEARNING DEFICITS IN AD TRANSGENIC RAT MODEL (2016) (0)
AMYLOID-INDUCED MICROGLIAL ACTIVITY IN THALAMOCORTICAL CIRCUITS PREDICTS SUBSEQUENT COGNITIVE DECLINE (2016) (0)
Young man with progressive speech impairment and weakness (2011) (0)
Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology? (2018) (0)
Dementia and Bioethics (2016) (0)
LATERAL TEMPORAL AMYLOID LOAD PREDICTS THE PROGRESSION TO ALZHEIMER’S DEMENTIA (2018) (0)
Cerebral cortical thickness in a subject lacking large myelinated afferents (2009) (0)
THE TRANSLATIONAL BIOMARKERS IN AGING AND DEMENTIA: TRIAD, A BIOMARKER ORIENTED COHORT (2019) (0)
Comparison of global and voxel-based diagnostic classification using [18F]florbetapir ROC estimates (2015) (0)
LONGITUDINAL ASSESSMENT OF THE NOVEL TAU TRACER [18F]MK-6240 FOR THE USE IN CLINICAL TRIALS (2019) (0)
REGIONAL PATTERNS OF TAU DEPOSITION DRIVEN BY LOCAL AMYLOID ACCUMULATION RECAPITULATE BRAAK STAGES IN AD (2018) (0)
Declines in entorhinal cortex structural connectivity in amnestic mild cognitive impairment (2011) (0)
Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study (2015) (0)
VASCULAR MEDICAL TREATMENTS INFLUENCE THE ASSOCIATION BETWEEN VASCULAR BURDEN AND AMYLOID PATHOLOGY IN ASYMPTOMATIC INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE (2019) (0)
Apolipoprotein E ε4 associates with microglial activation in early Braak regions independently of amyloid‐β and tau (2022) (0)
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum (2021) (0)
NEURODEGENERATION ASSOCIATED WITH LONGITUDINAL CHANGES OFAβ1-42 AND FIBRILLARY AMYLOID (2014) (0)
Foregoing Anesthesia Entirely : Resting-State Functional MRI of Completely Awake Rats (2013) (0)
A Devoted Wife with an Atypical Finding (2021) (0)
Man with gait impairment and urine incontinence (2011) (0)
Regional patterns of amyloidosis and synaptic dysfunction associated with auditory verbal learning: A PET study utilizing FDG and AV45 from ADNI (2012) (0)
Functional brain network subtypes are associated with Alzheimer's disease biomarkers in an aging, high-risk, cognitively normal cohort: The prevent-alzheimer's disease study (2015) (0)
Role of astrogliosis in the relationship between cerebrovascular burden and Alzheimer’s disease pathology (2022) (0)
A Young Missionary with Problems Quoting the Bible (2021) (0)
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology. (2023) (0)
Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24-months follow-up in cognitively normal subjects (2015) (0)
NOVEL TOOLBOX FOR PERFORMING VOXEL-WISE GENERALIZED LINEAR REGRESSION WITH MULITPLE VOLUMETRIC COVARIATES IN LONGITUDINAL DATA (2016) (0)
TRIAD multi‐dimensional biobank for biomarker discovery (2022) (0)
[P2–475]: WITHDRAWN (2017) (0)
Involvement of specific striatal subregion contributes to executive deficits in Alzheimer disease (2023) (0)
Examining the Locus Coeruleus Norepinephrine System With Neuromelanin-Sensitive MRI: Applications in Psychiatric and Neurodegenerative Illness (2022) (0)
PRE-CLINICAL CHARACTERIZATION OF HUMANIZED, BLOOD-BRAIN BARRIER (BBB)-PENETRATING, AMYLOID-β (Aβ) OLIGOMER-TARGETING FUSION PROTEIN (2018) (0)
Canada-China Cohort Study of early-onset familial Alzheimer's disease (2013) (0)
ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS (2017) (0)
Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum (2023) (0)
Genome-wide association study in PET imaging longitudinal data (2015) (0)
Assessment of hippocampal volumetry in transgenic Alzheimer’s disease rats (2013) (0)
IN VIVO AND IN VITRO DEMONSTRATION OF [18F]THK5351 BINDING TO MONOAMINE OXIDASE–B IN THE HUMAN BRAIN (2017) (0)
CORTICAL IRON DEPOSITION IN ALZHEIMER’S DISEASE CONTRASTS WITH AGE-RELATED SUBCORTICAL DEPOSITION (2019) (0)
Situating tau pathology and neuroinflammation along the principal gradients of brain organisation in Alzheimer’s disease (2022) (0)
Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum (2022) (0)
LONGITUDINAL EVALUATION OF TAU PROPAGATION USING [18F]MK-6240 (2019) (0)
Tau deposition assessed by [18F]MK6240 PET is associated with longitudinal decrease in grey matter density across the spectrum of Alzheimer’s disease (2020) (0)
A Young Man with Memory and Walking Difficulties (2021) (0)
Brain PET Oral 6: Neurodegenerative Disorders (2009) (0)
AMYLOID-B AND HYPERPHOSPHORYLATED TAU SYNERGY DRIVES CLINICAL PROGRESSION TO ALZHEIMER’S DISEASE (2016) (0)
AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN THE AD BRAIN: MICROPET LONGITUDINAL STUDY (2018) (0)
PREDICTING TAU PATHOLOGY PROGRESSION IN ALZHEIMER’S DISEASE BY MATHEMATICAL SIMULATION: FURTHER RESULTS AND PRIORITISATION OF MODIFICATIONS FOR FURTHER IMPROVEMENTS (2019) (0)
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals (2021) (0)
Interaction between amyloid and neuroinflammation on apathy along the Alzheimer’s disease spectrum (2020) (0)
THE EFFECT OF LUMBAR PUNCTURE ON THE RETENTION OF THE PREVENT-AD COHORT AD (2016) (0)
Posterior cingulate network adaptation in Alzheimer's disease (2013) (0)
NEURODEGENERATION MEDIATES AND MODERATES THE EFFECT OF AMYLOID AND TAU ON LONGITUDINAL COGNITION IN MILD COGNITIVE IMPAIRMENT (2019) (0)
HYPOMETABOLISM AND CORTICAL ATROPHY IN [18F]FLORBETAPIR ACCUMULATORS AND NON-ACCUMULATORS (2014) (0)
VOXEL-BASED POWER CALCULATION AND THRESHOLDS PREDICTIVE OF IMMINENT NEURODEGENERATION FOR PRECLINICAL ALZHEIMER’S DISEASE CLINICAL TRIALS (2017) (0)
Clinical relevance of three‐range cutpoints in Alzheimer’s disease CSF biomarkers (2021) (0)
Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort (2023) (0)
Brain imaging using CT and MRI (2021) (0)
HIPPOCAMPAL ATROPHY IN THE MCGILL-R-THY1-APP RAT MODEL OF ALZHEIMER'S DISEASE: A FOLLOW UP STUDY (2014) (0)
COMPARISON BETWEEN MONOAMINE OXIDASE B INHIBITION ON THE UPTAKE OF [18F]THK5351 (2017) (0)
[18F]TRACK, a PET tracer for imaging of tropomyosin receptor kinases (Trk): efficient radiosynthesis and preliminary evaluation in the TgF344‐AD rat model of Alzheimer’s disease. (2022) (0)
Siblings with a Fatal Cause of Rapidly Progressive Dementia (2021) (0)
NEUROPSYCHIATRIC SYMPTOMS RELATE TO TAU BUT NOT AMYLOID IN ALZHEIMER’S DISEASE (2019) (0)
Concerns about the Future (2021) (0)
EMOTIONAL MODULATION OF MEMORY ACROSS THE ALZHEIMER’S DISEASE SPECTRUM AND ASSOCIATION WITH GREY MATTER DENSITY (2019) (0)
A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease (2022) (0)
Cognitive health mediates the effect of hippocampal volume on COVID‐19‒related knowledge or anxiety change during the COVID‐19 pandemic (2021) (0)
Radiosynthesis of cis‐4‐[124I]iodo‐L‐proline as a prototype probe for imaging anterograde axoplasmic transport systems using positron emission tomography (PET) (2007) (0)
AMYLOID-DEPENDENT AND AMYLOID-INDEPENDENT EFFECTS OF TAU ON CLINICAL STATUS (2019) (0)
THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION (2018) (0)
NEUROPLASTICITY-BASED VISUAL ATTENTION TRAINING AND THE EXPRESSION OF ACETYLCHOLINE IN HEALTHY OLDER ADULTS (2018) (0)
NOVEL TOOLBOX FOR PERFORMING VOXEL-WISE GENERALIZED LINEAR REGRESSION WITH MULITPLE VOLUMETRIC COVARIATES IN LONGITUDINAL DATA (2016) (0)
LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER’S DISEASE (2019) (0)
Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration (2022) (0)
Association of brain amyloidosis and metabolism with the Trail Making Test in MCI and Alzheimer's disease (2012) (0)
SNAP25 reflects amyloid‐ and tau‐related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimer’s disease spectrum (2020) (0)
Olfactory identification is associated with CSF tau/abeta42 ratios in cognitively normal adults at high risk of Alzheimer's disease (2015) (0)
Macrophage Scavenger Receptor 1 in the CSF pre‐symptomatic with a parental history of AD and in the cortex of autopsy‐confirmed Alzheimer’s Disease cases. (2022) (0)
P.6.065 MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding potentials (2003) (0)
AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN AD BRAIN: MICROPET LONGITUDINAL STUDY (2018) (0)
Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 (2013) (0)
In vivo quantification of neurofibrillary tangles with [18F]MK-6240 (2018) (0)
Aβ-induced vulnerability propagates via the brain’s default mode network (2019) (0)
Plasma p‐Tau181 and p‐Tau231 offer complementary information to identify Alzheimer's disease pathophysiology (2021) (0)
SYNERGISM BETWEEN BRAIN AMYLOID ACCUMULATION AND NEURONAL INJURY IN CORTICAL-SUBCORTICAL CIRCUITS CAUSES MEMORY DECLINES IN ANIMAL MODELS (2016) (0)
Regional patterns of amyloidosis and synaptic dysfunction associated with auditory verbal learning: A PET study utilizing FDG and AV45 from ADNI (2012) (0)
PRE-SCREENING MACHINE LEARNING MODEL FOR β-AMYLOID POSITIVE ENRICHMENT (2019) (0)
Microglia activation predicts tau positivity beyond Aβ in Alzheimer’s disease (2021) (0)
PET TAU AND AMYLOID SYNERGISM WITHIN THE DEFAULT MODE NETWORK DETERMINES THE CLINICAL STATUS IN THE PREDEMENTIA PHASE OF ALZHEIMER’S DISEASE (2017) (0)
アミロイド,タウおよび神経変性(ATN)を用いたアルツハイマー病の生物学的定義の影響:血管変化,炎症,Lewy小体病理の役割について【JST・京大機械翻訳】 (2018) (0)
Biomarker modelling of Alzheimer's disease using in vivo Braak staging (2022) (0)
aMCI delay recall performance is associated with white and grey matter abnormalities in the left hippocampal formation: A DTI and cortical thickness study (2011) (0)
DOES SYNTHETIC DATA OVERSAMPLING IN FEATURE SELECTION IMPROVE THE CLASSIFICATION RATE IN ALZHEIMER'S DISEASE? (2016) (0)
Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease (2023) (0)
Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease (2022) (0)
Assessment of hippocampal volumetry in a transgenic Alzheimer's disease rat (2013) (0)
Brain imaging using PET and SPECT (2021) (0)
Application of two‐graph receiver operating characteristics for defining intermediate amyloid‐beta CSF cutoffs (2020) (0)
APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles (2023) (0)
MOVING AWAY FROM SINGLE AD-SIGNATURE ROI: ASSESSING THE RELATIONSHIP BETWEEN WHOLE-BRAIN GRAY MATTER PATTERN, AD PATHOLOGY, AND COGNITION IN HEALTHY ELDERLY AT RISK OF AD (2017) (0)
NEURODEGENERATION ASSOCIATED WITH LONGITUDINAL CHANGES OF AB1-42 AND FIBRILLARY AMYLOID (2014) (0)
AMYLOID-β AND HYPERPHOSPHORYLATED TAU SYNERGY DRIVES CLINICAL PROGRESSION TO ALZHEIMER’S DISEASE (2016) (0)
Revising the Diagnostic Criteria for Alzheimer’s Disease: The Use of Biomarkers and Attendant Ethical Implications (2013) (0)
Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice (2021) (0)
ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER’S DISEASE (2017) (0)
IN VITRO QUANTIFICATION OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE: AN [18F]T807 AUTORADIOGRAPHIC STUDY (2014) (0)
LOGICAL MEMORY DEFICITS ACROSS ALZHEIMER’S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF TAU PROPAGATION PREDICTED BY BRAAK STAGING (2018) (0)
Simultaneous Mass Spectrometric quantification of multiple p‐tau species in plasma – findings along the Alzheimer´s disease continuum (2022) (0)
Association between left hemisphere MK6240 uptake and language dysfunction in aging and Alzheimer’s disease (2020) (0)
LACK OF SELF-AWARENESS OF COGNITIVE DEFICITS PREDICTS METABOLIC DECLINE IN MILD COGNITIVE IMPAIRMENT (2017) (0)
Epistasis analysis links immune cascades and cerebral amyloidosis (2015) (0)
Man who stopped drinking (2011) (0)
COGNITIVE PERFORMANCE FOR VERBAL MEMORY AND SEMANTIC VERBAL FLUENCY AS A FUNCTION OF TAU PROTEIN LEVELS (2018) (0)
POLYMORPHISM IN CYTOCHROME P450 GENE IS ASSOCIATED WITH ALZHEIMER’S PATHOLOGY (2016) (0)
A.7 In vivo hippocampal mGluR5 abnormalities predict MTLE post-surgical outcome (2021) (0)
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly (2022) (0)
INCREASED PRO-INFLAMMATORY SIGNALING AND EVIDENCE OF ALZHEIMER’S DISEASE PATHOLOGY IN HEALTHY OLDER ADULTS AT RISK FOR AD (2017) (0)
Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress (2018) (0)
Endocannabinoid System Biomarkers in Alzheimer's Disease. (2022) (0)
Young man with behavioral symptoms (2011) (0)
The Forgetful Golfer (2021) (0)
ASSOCIATION OF [18F]MK6240 PET TAU BINDING WITH CLINICAL DIAGNOSIS, APOE4, COGNITION, AMYLOID, AGE, AND BRAAK STAGES ACROSS THE AD CLINICAL SPECTRUM (2018) (0)
THE EFFECT OF PROTON PUMP INHIBITORS AND CYP2C19 ON AMYLOID PATHOLOGY (2018) (0)
Adapting to the COVID‐19 pandemic in cohort studies: Validation of online assessments of cognition and neuropsychiatric symptoms in an aging population (2021) (0)
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe (2021) (0)
Characterization of an automated method to segment the human locus coeruleus. (2023) (0)
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions (2022) (0)
Consequences of Metabolic Disruption in Alzheimer’s Disease Pathology (2019) (0)
Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study (2023) (0)
PET and tissue autoradiography evidence of decline of metabotropic glutamate receptor type 5 (mGluR5) in the prefrontal cortex of Alzheimer's disease (2011) (0)
Neuropsychiatric symptoms herald metabolic decline in Alzheimer’s disease (2020) (0)
Different criteria modify Alzheimer’s disease diagnosis and prognosis (2022) (0)
Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. (2023) (0)
Monitoring disease pathophysiology longitudinally using multiparametric PET acquisitions: The McGill TRIAD cohort (2020) (0)
SUBTHRESHOLD LEVEL TAU DEPOSITION OCCURS PRIOR TO SUBTHRESHOLD AMYLOID DEPOSITION IN COGNITIVELY NORMAL ELDERLY INDIVIDUALS (2019) (0)
Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP rat (2015) (0)
Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease (2022) (0)
In vivo characterization of glutamatergic vulnerability in behavioral variant FTD: An [11C]ABP688 PET/ VBM /DBM study (2013) (0)
SYNERGISM BETWEEN BASELINE AMYLOIDOSIS AND NEURONAL INJURY AS DETERMINANTS OF LEARNING DEFICITS IN ALZHEIMER'S DISEASE TRANSGENIC RAT MODEL (2016) (0)
EARLY REMODELING OF BRAIN METABOLIC ARCHITECTURE IN A TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE (2014) (0)
Case of young man smoking pot but with a mother who died of dementia (2011) (0)
WHITE MATTER ABNORMALITIES AND STRUCTURAL PARIETAL DISCONNECTIONS IN ALZHEIMER'S DISEASE (2014) (0)
Brain TSPO expression is associated with plasma pTau181 & pTau231 across the AD spectrum (2022) (0)
Dopamine D2/3 receptor binding in aphakia mice measured by microPET (2005) (0)
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression (2019) (0)
WHITE MATTER ABNORMALITIES AND STRUCTURAL PARIETAL DISCONNECTIONS IN ALZHEIMER'S DISEASE (2014) (0)
Woman with dementia and hepatic disease (2011) (0)
Adapting to reality: Effect of Online Assessments as Compared to In‐Person Assessments (2022) (0)
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains (2022) (0)
REGIONAL PATTERNS OF TAU DEPOSITION DRIVEN BY LOCAL AMYLOID ACCUMULATION RECAPITULATE BRAAK STAGES IN AD (2018) (0)
COGNITIVE DECLINE IS DRIVEN BY THE REGIONAL SYNERGISM BETWEEN AMYLOID LOAD AND HYPOMETABOLISM IN MILD COGNITIVE IMPAIRMENT (2016) (0)
Brain TSPO expression is associated with plasma pTau181 & pTau231 across the AD spectrum (2022) (0)
GABAergic system in Alzheimer’s disease: a systematic review with meta‐analysis (2022) (0)
Elderly Man Repeating Questions about Upcoming Appointments (2021) (0)
Tau accumulation using [18F]MK6240 PET is associated with increase in executive dysfunction in prodromal AD (2021) (0)
Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo (2023) (0)
Diagnostic tests: novel biomarkers (2021) (0)
NSAIDS FOR AD PREVENTION? NAPROXEN ENTERS THE CNS WITHOUT APPARENT EFFECT ON CSF IMMUNE MARKERS (2019) (0)
CORRELATIONS BETWEEN VARIOUS MOCA COGNITIVE DOMAIN ASSESSMENTS AND REGIONAL BRAIN FDG-PET HYPOMETABOLISM (2014) (0)
Does donepezil improve visual stimuli detection and perceptivo-cognitive performance of heathy young adults ? (2015) (0)
A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study (2021) (0)
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease (2021) (0)
CSF INFLAMMATORY AND LIPID TRANSPORTER PROTEINS PREDICT GREY MATTER DENSITY LONGITUDINAL CHANGES (2016) (0)
SUICIDAL IDEATION IS PREVALENT IN BOTH ASYMPTOMATIC AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE MUTATION AND NON-MUTATION CARRIERS (2018) (0)
Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. (2023) (0)
Woman with visual complaints (2011) (0)
Neural correlates of disaster-related prenatal maternal stress in young adults from Project Ice Storm: Focus on amygdala, hippocampus, and prefrontal cortex (2023) (0)
Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology (2022) (0)
ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER’S DISEASE (2019) (0)
VOXEL-WISE LOGISTIC REGRESSION IMPROVES PREDICTION ACCURACY FOR DEVELOPING ALZHEIMER'S DISEASE (2016) (0)
A retinal deep phenotypingTM platform to predict the cerebral amyloid PET status in older adults (2021) (0)
ASSOCIATION OF VASCULAR RISK AND ALZHEIMER’S DISEASE PATHOLOGY WITH NEURODEGENERATION AND COGNITIVE DECLINE (2021) (0)
Microglial activation indexed by [11C]PBR28 is associated with synaptic depletion in the Alzheimer’s disease spectrum (2020) (0)
[18F]FLORBETAPIR ROC CURVE AT EVERY VOXEL REVELS A WIDE RANGE OF CORTICAL SUVR CUT-OFFS (2016) (0)
Association between tau uptake and verbal fluency converge in language centers (2022) (0)
Young man with slow cognitive decline (2011) (0)
AMYLOID-INDUCED MICROGLIAL ACTIVITY IN THALAMOCORTICAL CIRCUITS PREDICTS SUBSEQUENT COGNITIVE DECLINE (2016) (0)
Verbal fluency associated with tau accumulation and not amyloid deposition in the Alzheimer’s disease spectrum (2021) (0)
AMYLOID-BETA MODULATES CEREBRAL METABOLIC NETWORK IN RATS AND HUMANS (2017) (0)
Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia (2022) (0)
Associations between neutrophils and amyloid deposition in the Alzheimer’s disease spectrum (2021) (0)
AMYLOIDOSIS CHANGES ASSOCIATIONS BETWEEN HIPPOCAMPUS VOLUME AND BRAIN METABOLIC DECLINES (2014) (0)
UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXEL-WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS (2018) (0)
Comparison of global and voxel-based diagnostic classification using [18F]florbetapir ROC estimates (2015) (0)
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease? (2016) (0)
Neuroinflammation imposes vulnerability to tau propagation (2020) (0)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (0)
Modeling the trajectory of tau deposition in autosomal‐dominant Alzheimer’s disease using the high‐affinity tau tracer [ 18 F]MK6240: Neuroimaging / Optimal neuroimaging measures for tracking disease progression (2020) (0)
The role of IGFBP2 in pre‐symptomatic Alzheimer's disease: a multimodal longitudinal study of cognitively unaffected individuals with a family history of sporadic Alzheimer’s disease (2022) (0)
Accelerated microPET Transmission Imaging (2008) (0)
Frontal tau pathology underlies behavioural / dysexecutive clinical presentations of Alzheimer’s disease (2020) (0)
27 EOFAD: Opportunities for proof-of-concept studies to modify disease progresssion (2012) (0)
HOW SHOULD WE ASSESS FUNCTIONAL PERFORMANCE IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT (MCI)? (2014) (0)
Extremely Early-Onset Frontotemporal Dementia: A Case Report and Literature Review (2022) (0)
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease (2021) (0)
Elderly lady with right-sided visual hallucinations (2011) (0)
Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology (2021) (0)
Tau‐load in the lingual gyrus impacts anxiety levels during the COVID‐19 pandemic in participants of longitudinal observational studies in aging (2021) (0)
Clusterin is associated with Alzheimer’s disease biomarkers and cognitive scores in the pre‐symptomatic phase of the disease. (2022) (0)
Normative values of neuromelanin-sensitive MRI signal in older adults obtained using a standard protocol for acquisition and analysis (2022) (0)
Language impairment in the genetic forms of behavioural variant frontotemporal dementia (2022) (0)
Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales (2022) (0)
PRECLINICAL ASSESSMENT OF KAL-ABP TARGET ENGAGEMENT AND EFFICACY USING PET, MRI AND CSF BIOMARKERS (2017) (0)
EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNO-RESPONSE (2014) (0)
Tau phosphorylation is more closely associated with amyloid‐β plaques than with tau neurofibrillary tangles (2022) (0)
ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER’S DISEASE (2017) (0)
Differential impact of amyloidosis and tau pathology on brain metabolism (2013) (0)
Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer's disease spectrum. (2022) (0)
The effect of age on tau burden is dependent on amyloid status in late‐onset Alzheimer's disease (2020) (0)
Amyloid (a), tau (t) and voxel‐based morphometry (n) correlates of visual memory performance (2020) (0)

This paper list is powered by the following services:

Pedro Rosa Rosa-neto's Academic­Influence.com Rankings

Pedro Rosa Rosa-neto's Degrees

Why Is Pedro Rosa Rosa-neto Influential?

Pedro Rosa Rosa-neto's Published Works

Published Works

Pedro Rosa Rosa-neto's AcademicInfluence.com Rankings